Navigation Links
Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
Date:3/31/2008

d

by our market research resources that there are approximately two

million bone grafting procedures in the United States every year. The

market for orthopedic biomaterials used in these procedures was

estimated to be approximately $4 billion in 2006. In addition, the

fastest growing segment of this market is recombinant protein products

which is expected to grow to $2.9 billion by 2012.

-- We are developing second-generation technetium-based imaging agents to

aid in the diagnosis of PD, Dementia with Lewy Bodies (DLB), and

Attention Deficit Hyperactivity Disorder (ADHD). We have previously

demonstrated in non-human primate studies that our technetium-based

agents are effective in binding the to DAT in sufficient quantity and

with high-selectivity to provide a readable image in the normal brain.

During 2007, we devised a new radiolabeling procedure for our

technetium agents that results in a high purity, high yield product as

a prelude to obtaining definitive images in non-human primates.

Continued Intellectual Property (IP) leadership notably in regenerative

therapeutics.

Alseres' IP portfolio includes issued, allowed or granted patents from the

U.S. and other key countries worldwide. During 2007, the company

submitted 14 new patent applications covering our regenerative

therapeutics, molecular imaging, and neurodegenerative disease assets. We

were granted three new patents covering CETHRIN, four additional patents

covering other regenerative therapies and one patent covering our DAT

blocker platform.

Business & Operational Highlights

Licensed Phase I/IIa Regenerative Therapeutics Program in acute SCI.

In December 2006, Alseres licensed, from BioAxone Therapeutic, Inc. of

Montreal, Canada, development and commercialization rights of CETHRIN, as

<
'/>"/>
SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Alseres Pharmaceuticals to Host 2007 Financial Results Conference Call
2. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
3. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
4. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
5. Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the Peoples Republic of China
6. Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt
7. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
8. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
9. Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations
10. Investor Alert from Cauley Bowman Carney & Williams, PLLC: Update on Proposed Acquisition of CollaGenex Pharmaceuticals, Inc. - CGPI
11. Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... (PRWEB) July 25, 2014 The Conferee ... for Topics for Conferee Networking. These two-hour sessions provide ... to meet and resolve problems, discuss new techniques, or ... deadline to submit a topic for consideration is August ... pittcon.org . The Conferee Networking committee will review the ...
(Date:7/25/2014)... AVIV, Israel , July 25, 2014  Galmed ... clinical-stage biopharmaceutical company focused on the development and commercialization ... liver diseases and cholesterol gallstones, today announced financial results ... First Half 2014 Financial Summary: , Reported cash ... 2014, compared with $137,000 at December 31, 2013.  ...
(Date:7/25/2014)... 25, 2014 At the request of ... a 60-day extension for the public comment period (Docket ... for Model Aircraft established by Congress as part of ... 60-day extension establishes the new deadline for comments as ... of Transportation/FAA notice published in the Federal Register on ...
(Date:7/24/2014)... York, NY - July 24, 2014 -- Keryx Biopharmaceuticals, ... from the long-term, randomized, active control Phase 3 study ... iron-based phosphate binder, for the treatment of hyperphosphatemia in ... PERFECTED study (PhosphatE binding and iRon delivery with FErric ... Journal of the American Society of Nephrology ...
Breaking Biology Technology:Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6FAA Grants Comment Extension at the Request of AMA 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4
... INTRODUCTION , ... encoded bacterial enzymes which hydrolyze β -lactam antibiotics. The majority of ... One successful approach to combating the serine active site β -lactamases ... in combination with a β -lactam antibiotic 4 . , There ...
... , Evelyn McGown and Michael Su , ... fluorogenic oligonucleotide probes developed by Kramerand associates to detect ... They are single-stranded oligonucleotides that exist in a ... which bind together to form a stem. Thestrained loop ...
... , Anne T. Ferguson, Ph.D., ... , , INTRODUCTION , This ... XS from Molecular Devices to study the performance of the LIVE/DEAD ... two fluorescent dyes, calcein AM (cal AM) and ethidium homodimer (EthD-1), ...
Cached Biology Technology:A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 2A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 3A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 4A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 5A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 6Measurement of Molecular Beacons in the SpectraMax Gemini Spectrofluorometer (MaxLine Application Note #36) 2Measurement of Molecular Beacons in the SpectraMax Gemini Spectrofluorometer (MaxLine Application Note #36) 3Measurement of Molecular Beacons in the SpectraMax Gemini Spectrofluorometer (MaxLine Application Note #36) 4LIVE/DEAD Viability/Cytotoxicity Assay for Animal Cells Using the SpectraMax Gemini XS Fluorescence Microplate Reader (MaxLine Application Note #43) 2LIVE/DEAD Viability/Cytotoxicity Assay for Animal Cells Using the SpectraMax Gemini XS Fluorescence Microplate Reader (MaxLine Application Note #43) 3LIVE/DEAD Viability/Cytotoxicity Assay for Animal Cells Using the SpectraMax Gemini XS Fluorescence Microplate Reader (MaxLine Application Note #43) 4LIVE/DEAD Viability/Cytotoxicity Assay for Animal Cells Using the SpectraMax Gemini XS Fluorescence Microplate Reader (MaxLine Application Note #43) 5
(Date:7/25/2014)... associate professor of biomedical engineering at the University ... tissue engineering and artificial organ development., "Introduction to ... guide to entering into the field of artificial ... of biomedical engineering at UH, served as a ... while there are other published books on the ...
(Date:7/25/2014)... opened the way for the development of new lines of ... barley production is second only to wheat with 7-8 million ... important diseases of barley. , Senior Research Scientist Dr Alan ... on the cell walls of barley plants that block the ... by the ARC Centre of Excellence in Plant Cell Walls ...
(Date:7/25/2014)... Spina bifda (SB) is a complex congenital central ... incomplete closing of the neural tubes during the ... spasticity, urinary and fecal incontinence and neurocognitive retardation. ... their quality of life. Researchers at Ankara Physical ... investigate the functional performance in children with SB, ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2New hope for powdery mildew resistant barley 2
... effort to make data storage more cost-effective, a group of ... Karlsruhe Institute of Technology in Germany have created a DNA-based ... (UV) light to make it possible to encode information. The ... Applied Physics Letters , consists of a thin film of ...
... Athens, Ga. The knowledge that bacteria possess adaptable immune ... invaders is relatively new to science, and researchers across the ... to apply that knowledge in industry and medicine. ... how to harness this bacterial immune system to selectively target ...
... Ore. - Newly published research by scientists at Oregon ... how early embryonic stem cells develop and take part ... took place at OHSU,s Oregon National Primate Research Center, ... chimeric monkeys -- monkeys developed from stem cells taken ...
Cached Biology News:UGA scientists 'hijack' bacterial immune system 2UGA scientists 'hijack' bacterial immune system 3OHSU research produces the world's first primate chimeric offspring 2
activating transcription factor 4 (tax-responsive enhancer element B67),...
Request Info...
2-min, single-step add-mix-measure assay for luciferase expression and HTS in mammalian cells. Linear detection range: 2 fg to 46 ng luciferase....
Trop-2 Purified Anti-Human clone 162-46, Isotype Mouse IgG 1 , 100 µg Consult technical datasheet for details....
Biology Products: